ProMetic Life Sciences (PLI) Shares Up 5.3%
ProMetic Life Sciences Inc. (TSE:PLI) shares shot up 5.3% during mid-day trading on Friday . The company traded as high as C$1.65 and last traded at C$1.59. 1,226,966 shares traded hands during trading, a decline of 29% from the average session volume of 1,729,067 shares. The stock had previously closed at C$1.51.
A number of brokerages have recently issued reports on PLI. Cantor Fitzgerald reiterated an “overweight” rating on shares of ProMetic Life Sciences in a report on Monday, November 20th. National Bank Financial reduced their price objective on shares of ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating for the company in a report on Wednesday, November 15th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of C$3.50.
The firm has a market capitalization of $1,100.00, a price-to-earnings ratio of -8.88 and a beta of 2.39.
ILLEGAL ACTIVITY WARNING: “ProMetic Life Sciences (PLI) Shares Up 5.3%” was originally reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.dailypolitical.com/2018/01/12/prometic-life-sciences-pli-shares-up-5-3.html.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.